Your session is about to expire
← Back to Search
Computerized Decision Support for Blood Clot Prevention (DC-eALERT Trial)
DC-eALERT Trial Summary
This trial is a single-center, 400-patient, randomized controlled trial of an EPIC Best Practice Advisory (BPA; alert-based computerized decision support tool) to increase prescription of extended-duration post-discharge thromboprophylaxis and decrease symptomatic VTE in high-risk patients hospitalized with medical illness.
DC-eALERT Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.DC-eALERT Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am over 40, hospitalized for a serious illness, have limited mobility, not on blood clot prevention meds, and have another risk factor for blood clots.I was given medication to prevent blood clots when I left the hospital.
- Group 1: Alert
- Group 2: No Alert
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
To what extent is this research project being supported by participants?
"Indeed, the information available on clinicaltrials.gov verifies that this trial is presently accepting applications from patients. The study was initially advertised on February 1st 2019 and has most recently been revised on April 5th 2022. 400 individuals are being recruited at one site for participation in the experiment."
Is there still an opportunity to participate in this research endeavor?
"Affirmative. Clinicaltrials.gov data reveals that this medical study, which was originally posted on February 1st 2019, is actively recruiting. This evaluation requires 400 test subjects from a single trial site."
Share this study with friends
Copy Link
Messenger